Treatment results were immediate
Dosing protocols are based on clinical research, pharmacokinetic data, and community experience with the peptide
It typically presents as macrocytic megaloblastic anemia and neurological impairments, including sensory and motor disfunctions, predominantly in the lower extremities, ataxia, and in more advanced stages cognitive decline progressing to dementia, as well as psychiatric disturbances (Sanjay et al., 2022
This is for you if Patients on tirzepatide who experience fatigue during titration Patients with low or borderline B12 levels Patients who want fewer injections during their weight-management protocol This isn't for you if All safety information for tirzepatide applies see the Tirzepatide product page
Indoor or night-shift work
Available in 2 MG, 5 MG and 10 MG vials, supplied as lyophilized powder for reconstitution